
Classic GHRP with orexigenic side effect — strongly stimulates GH release and appetite. Ideal for bulk phases.
Ranges cited in research literature. Not a usage recommendation. For research use only.
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is the first growth-hormone secretagogue that worked in vivo, developed by Cyril Bowers at Tulane University and described in 1984, fifteen years before ghrelin was discovered. Its existence was in fact what led to the identification of the GHSR-1a receptor and later of its natural ligand. It is a hexapeptide with two D-amino acids that give it stability against peptidases.
It acts as a ghrelin-receptor agonist in the pituitary and hypothalamus, provoking an intense GH release that in humans is synergistic with GHRH: giving both together produces more GH than the sum of each, a 1990s finding that remains the basis of GHRH + secretagogue combinations. Unlike ipamorelin, GHRP-6 also moderately raises ACTH, cortisol and prolactin, and shares with ghrelin a marked orexigenic effect: it increases appetite quickly and noticeably.
Human studies are old and focused on the physiology of GH secretion and on diagnostic use; it was never developed as a medicine and holds no approval. Its effect on appetite, cortisol and prolactin is what drove the design of more selective secretagogues. It shares the class considerations on GH and IGF-1 and is on the World Anti-Doping Agency list. Renova distributes it as the acetate salt, for research only.
| Class | First-generation GH secretagogue (GHRP), ghrelin-receptor agonist |
| Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (hexapeptide, acetate salt) |
| CAS | 87616-84-0 |
| Origin | Cyril Bowers, Tulane University, 1984 |
| Hormonal profile | Releases GH; moderately raises ACTH, cortisol and prolactin; markedly orexigenic |
| Synergy | GHRH + GHRP-6: GH release greater than the sum (documented in humans) |
| Half-life | Short (on the order of minutes to a few hours) |
| Regulatory status | Not approved; WADA list (S2) |
Because it activates the same receptor as ghrelin, the appetite hormone the stomach produces, in the hypothalamus. It is the compound's most recognizable effect and appears shortly after administration in studies. Later secretagogues such as ipamorelin were designed partly to avoid it.
Both activate the ghrelin receptor and release GH, but GHRP-6 also raises ACTH, cortisol and prolactin and stimulates appetite; ipamorelin, in Novo Nordisk's studies, altered neither those hormones nor appetite. GHRP-6 is older and less selective.
Yes, in 1984; ghrelin was identified in 1999. GHRP-6 was a designed molecule that worked without anyone knowing which receptor it acted on; the search for that receptor led to GHSR-1a (1996) and then to its natural ligand. It is a classic case of reverse pharmacology.
In research, yes, because the two classes potentiate each other: it was precisely with GHRP-6 that the synergy with GHRH was first described in humans. In Renova's catalog the available GHRH analogs are sermorelin, Mod GRF 1-29 (CJC-1295 without DAC) and CJC-1295 with DAC.
Related reading: GHRP-6: GH Secretagogue and Ghrelin · CJC-1295 + Ipamorelin: The Most-Studied GH Stack
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty